5 Nov 17

Arsanis closes Series A funding for $10 million Arsanis, Inc, a recently founded biotechnology company focused on the advancement of anti-infective monoclonal antibody therapeutics, today announced the closing of a Series A financing with a total funding amount of $10 million. Proceeds from the initial financing will be used to advance several applications in the anti-microbial infectious disease area. The financing involved equivalent contributions from OrbiMed Advisors, Polaris Venture Partners and SV Existence Sciences Les comprim√©s d’√©rection . Managing Partners, Carl Gordon, Terry McGuire and Mike Ross joined the founders on Arsanis’ Table of Directors. Arsanis was founded in the fall of 2010 by Dr.

A new study by researchers at the University of Pittsburgh provides examined this subject in people with rheumatoid arthritis , osteoarthritis and fibromyalgia . The study involved 315 arthritis sufferers who completed a specially-designed study that contained questions on computer use, irritation experienced while using a chair, desk, keyboard, mouse and monitor, and problems associated with each device. The outcomes showed that many people with arthritis experience both pain and issues that could business lead to work constraints: 84 percent of respondents reported a problem with pc use related to their underlying disorder and 77 percent reported some pain related to computer make use of. Of the three categories of disease, more respondents with FM reported severe discomfort significantly, more problems and higher limitations linked to computer use than people that have OA or RA.